Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.38
-0.04 (-1.85%)
Market open: Aug 12, 2026, 11:31 AM EDT
2.41
-0.02 (-0.82%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-08-06 | S-3 | d140435ds3.htm |
| 2026-08-06 | 8-K | lxrx-20260806.htm |
| 2026-05-07 | 8-K | lxrx-20260507.htm |
| 2026-05-07 | 10-Q | lxrx-20260331.htm |
| 2026-05-06 | 8-K | lxrx-20260504.htm |
| 2026-04-30 | 8-K | lxrx-20260430.htm |
| 2026-03-16 | DEFA14A | a2026proxynotice04-22x2026.htm |
| 2026-03-16 | DEF 14A | lxrx-20260316.htm |
| 2026-03-16 | ARS | a2025annualreport.htm |
| 2026-03-05 | 8-K | lxrx-20260305.htm |